Abstract
HAART has been shown to improve the course of HIV disease by reducing viral load and increasing the CD4+ T lymphocyte count [1, 2]. Consequently, there have been decreases in the rate of progression to AIDS and subsequent significant decreases in the mortality rate [3]. Most of the published literature on the effectiveness of HAART on improved health status is restricted to white men, and only a few studies have directly addressed the survival benefit of HAART for injection drug users and women, who today constitute a substantial proportion of adults with HIV infection [4, 5].

This publication has 15 references indexed in Scilit: